Table 2.

Comparing the motor nerve conduction measurements between the two study groups

	n-3 PUFAs (Mean ± SD)	Placebo (Mean ± SD)	Mean Difference	95 % CI, P-value
Tibial nerve
DML 1 (ms)	4.82 ± .81	5.80 ± 1.31	−.98	−1.50 to −.46, <.001*
DML 2a	4.60 ± .79	5.70 ± .95	− .68	− 1.18 to −.17, .009**
% Changec	− 4.77	− 1.73
a-CMAP1(mV)	9.30 (5.62–13.72)	10.20 (5.60–15.30)	--	.696***
a-CMAP 2	10.20 (6.20–13.00)	6.10 (3.47–9.25)		.003b
% Change	9.68	− 40.20
MCV 1(m/s)	45.81 ± 6.61	43.06 ± 5.08	2.74	−.05 to 5.54, .054*
MCV 2	45.67 ± 6.18	42.34 ± 4.68	1.86	− .52 to 4.25, .123**
% Change	−.31	− 1.70
Peroneal nerve
DML 1 (ms)	4.34 ± .92	5.21 ± 1.44	−.87	−1.45 to −.30, .004*
DML 2	4.16 ± 1.04	5.02 ± 1.95	.08	− .78 to .94, .850**
% Change	− 3.93	− 3.65
a-CMAP1(mV)	4.00 (3.00–4.60)	2.80 (1.90–5.20)	--	.238***
a-CMAP 2	4.40 (3.10–5.30)	2.90 (1.17–4.75)		.217b
% Change	10.00	3.57
MCV 1(m/s)	47.59 ± 5.95	44.07 ± 6.91	3.51	.40 to 6.63, .028*
MCV 2	44.70 ± 5.30	43.60 ± 6.87	− 1.37	− 3.88 to 1.14, .278**
% Change	− 6.07	−1.07
Ulnar nerve
DML 1 (ms)	3.12 ± .61	3.35 ± .59	−.23	−.51 to .060, .118*
DML 2	2.97 ± .55	3.33 ± .59	− .26	− .54 to .02, .073**
% Change	− 4.81	− .60
aCMAP1(mV)	11.85 (9.40–14.30)	12.40 (10.80–13.10)	--	.394***
a-CMAP 2	13.10 (10.10–15.00)	10.75 (10.00–13.60)		.033b
% Change	10.55	− 13.31
MCV 1(m/s)	63.01 ± 26.22	55.60 ± 10.89	7.42	−2.14 to 16.98, .126*
MCV 2	53.64 ± 16.72	53.98 ± 6.34	.07	−6.84 to 6.97, .984**
% Change	− 14.87	− 2.90

DML distal motor latency, a-CMAP amplitude of compound muscle action potential, MCV motor conduction velocity

*P value is reported based on Independent-Samples T-Test

**P value is reported based on the analysis of covariance, adjusted for baseline values

***P value is reported based on the Mann–Whitney U Test

^aOne month after the cessation of chemotherapy

^b P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)

^cPercent change in proportion to the baseline values